Is resistance useless? Multidrug resistance and collateral sensitivity

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Multidrug resistance (MDR) in cancer is often mediated by P-glycoprotein (P-gp), an efflux pump conferring resistance to various chemotherapeutics.
• P-gp expression leads to cross-resistance, limiting treatment efficacy and posing a significant clinical challenge.
• Existing strategies to overcome MDR have yielded limited clinical success over the past three decades.

Purpose of the Study:

• To review the phenomenon of collateral sensitivity (CS) in MDR cancer cells.
• To explore underlying mechanisms, such as reactive oxygen species generation, contributing to CS.
• To propose CS as a viable strategy for enhancing chemotherapy response.

Main Methods:

• Literature review of studies investigating MDR and CS in cancer.
• Analysis of proposed molecular mechanisms for collateral sensitivity.
• Synthesis of findings to propose therapeutic strategies.

Main Results:

• MDR cancer cells exhibit hypersensitivity to certain drugs, a phenomenon termed collateral sensitivity (CS).
• CS is a widespread effect in P-gp-mediated multidrug resistance.
• Hypotheses regarding the generality of CS include the role of reactive oxygen species.

Conclusions:

• Collateral sensitivity represents a significant, yet underexplored, aspect of multidrug resistance.
• Understanding the mechanisms of CS can provide novel therapeutic avenues.
• Exploiting collateral sensitivity offers a promising strategy to improve chemotherapy effectiveness in resistant cancers.